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Background: Tranexamic acid reduces death due to bleeding after trauma and postpartum haemorrhage.
Objective: The aim of the study was to assess if tranexamic acid is safe, reduces haematoma expansion
and improves outcomes in adults with spontaneous intracerebral haemorrhage (ICH).
Design: The TICH-2 (Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage) study was a
pragmatic, Phase III, prospective, double-blind, randomised placebo-controlled trial.
Setting: Acute stroke services at 124 hospitals in 12 countries (Denmark, Georgia, Hungary, Ireland, Italy,
Malaysia, Poland, Spain, Sweden, Switzerland, Turkey and the UK).
Participants: Adult patients (aged ≥ 18 years) with ICH within 8 hours of onset.
Exclusion criteria: Exclusion criteria were ICH secondary to anticoagulation, thrombolysis, trauma or
a known underlying structural abnormality; patients for whom tranexamic acid was thought to be
contraindicated; prestroke dependence (i.e. patients with a modified Rankin Scale [mRS] score > 4);
life expectancy < 3 months; and a Glasgow Coma Scale score of < 5.
Interventions: Participants, allocated by randomisation, received 1 g of an intravenous tranexamic acid
bolus followed by an 8-hour 1-g infusion or matching placebo (i.e. 0.9% saline).
Main outcome measure: The primary outcome was functional status (death or dependency) at day 90,
which was measured by the shift in the mRS score, using ordinal logistic regression, with adjustment for
stratification and minimisation criteria.
Results: A total of 2325 participants (tranexamic acid, n = 1161; placebo, n = 1164) were recruited from
124 hospitals in 12 countries between 2013 and 2017. Treatment groups were well balanced at baseline.
The primary outcome was determined for 2307 participants (tranexamic acid, n = 1152; placebo, n = 1155).
There was no statistically significant difference between the treatment groups for the primary outcome of
functional status at day 90 [adjusted odds ratio (aOR) 0.88, 95% confidence interval (CI) 0.76 to 1.03;
p = 0.11]. Although there were fewer deaths by day 7 in the tranexamic acid group (aOR 0.73, 95% CI 0.53
to 0.99; p = 0.041), there was no difference in case fatality at 90 days (adjusted hazard ratio 0.92, 95% CI
0.77 to 1.10; p = 0.37). Fewer patients experienced serious adverse events (SAEs) after treatment with
tranexamic acid than with placebo by days 2 (p = 0.027), 7 (p = 0.020) and 90 (p = 0.039). There was no
increase in thromboembolic events or seizures.
Limitations: Despite attempts to enrol patients rapidly, the majority of participants were enrolled and treated
> 4.5 hours after stroke onset. Pragmatic inclusion criteria led to a heterogeneous population of participants,
some of whom had very large strokes. Although 12 countries enrolled participants, the majority (82.1%)
were from the UK.
Conclusions: Tranexamic acid did not affect a patient’s functional status at 90 days after ICH, despite
there being significant modest reductions in early death (by 7 days), haematoma expansion and SAEs,
which is consistent with an antifibrinolytic effect. Tranexamic acid was safe, with no increase in
thromboembolic events.
Future work: Future work should focus on enrolling and treating patients early after stroke and identify
which participants are most likely to benefit from haemostatic therapy. Large randomised trials are needed.
Trial registration: Current Controlled Trials ISRCTN93732214.
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Plain English summary
Background
Stroke caused by bleeding in the brain [i.e. an intracerebral haemorrhage (ICH)] is a medical emergency.
Around one-third of such strokes are complicated by continuing bleeding, which usually occurs within the
first few hours after trauma and childbirth, and is associated with death or severe disability. Tranexamic
acid is a drug that is seen to reduce death from bleeding after trauma and childbirth.
Methods
The study enrolled adults within 8 hours of an ICH into this large randomised trial. Half of the participants
were given an injection of tranexamic acid and the other half placebo (in the form of salt water). The main
aim of the trial was to measure changes in recovery by a telephone questionnaire on how much the person
was able to do or needed help with 90 days after the stroke (i.e. functional status). Other measures included
amount of brain bleeding, complications after stroke (serious adverse events), drug side effects and death
within 7 days of stroke.
Results
A total of 2325 participants from 124 hospitals in 12 countries were enrolled between 2013 and 2017.
Participants treated with tranexamic acid had no significant difference in functional status 90 days after
stroke. There were small but significant reductions in brain bleeding, death in the first 7 days and
complications after stroke, and tranexamic acid was safe with no increased side effects.
Conclusion
Treatment with tranexamic acid did not result in a significant improvement in recovery at 90 days (i.e.
functional status), despite small reductions in the number of early deaths, amount of brain bleeding and
the number of complications. Larger trials are needed to confirm if these small benefits observed after
treatment with tranexamic acid can significantly improve functional status after stroke due to bleeding in
the brain (ICH).
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Scientific summary
Background
Although intracerebral haemorrhage (ICH) accounts for only 10–15% of all strokes, it is the most devastating
type of stroke, with a 30-day fatality rate of 40–50%. One year after ICH, 70–80% of survivors remain
dependent.
Haematoma expansion occurs in up to 38% of patients with ICH, mostly within the first few hours.
Haematoma expansion leads to higher mortality and worse functional outcome. The most widely researched
haemostatic agent in ICH, recombinant factor VIIa (rFVIIa), does not significantly reduce death or dependency.
Although a reduction in haematoma expansion has been reported, the benefit of this is probably offset by an
increase in thromboembolic events.
Tranexamic acid is an antifibrinolytic agent that acts on the plasmin-mediated pathway to prevent the
breakdown of a blood clot. It is an effective haemostatic agent in many bleeding conditions. In the Clinical
Randomisation of an Antifibrinolytic in Significant Haemorrhage – 2 [CRASH-2; CRASH Trial Collaborators.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with
significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32] trial,
involving 20,211 patients with major bleeding due to trauma, treatment with tranexamic acid significantly
reduced mortality [adjusted odds ratio (aOR) 0.91, 95% confidence interval (CI) 0.85 to 0.97], especially
when given within 3 hours of trauma. A subgroup analysis of patients with traumatic intracranial haemorrhage
in the trial showed a non-significant trend to reduced mortality (aOR 0.47, 95% CI 0.21 to 1.04), and death
or dependency (aOR 0.66, 95% CI 0.32 to 1.36). The CRASH-3 study is an ongoing randomised controlled
trial (RCT) that is assessing the effect of tranexamic acid on risk of death or disability in patients with
traumatic brain injury.
Treatment with tranexamic acid reduced bleeding-related death in women with postpartum haemorrhage in
the WOrld Maternal ANtifibrinolytic (WOMAN) trial [WOMAN Trial Collaborators. Effect of early tranexamic acid
administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage
(WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2105–16]
[n = 20,060; risk ratio (RR) 0.81, 95% CI 0.65 to 1.00], with the greatest effect in women given treatment
within 3 hours of childbirth (RR 0.69, 95% CI 0.52 to 0.91). Furthermore, an individual patient data meta-
analysis of the CRASH-2 and WOMAN trials highlights the need to administer tranexamic acid immediately.
Immediate treatment improved survival by > 70% and the survival benefit decreased by 10% for every
15 minutes of treatment delay until 3 hours, after which there was no benefit to the patient. There was
no increase of thromboembolic events with the treatment of tranexamic acid in both trials, although the
patients were younger and had fewer comorbidities than those with ICH.
The use of tranexamic acid in spontaneous ICH (SICH) has been studied in two small RCTs (Law ZK, Meretoja A,
Engelter ST, et al. Treatment of intracerebral haemorrhage with tranexamic acid – a review of current evidence
and ongoing trials. Eur J Stroke 2016;2:3–22; Al-Shahi Salman R, Law ZK, Bath PM, et al. Haemostatic
therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev 2018;4:CD005951).
The Tranexamic acid in IntraCerebral Haemorrhage (TICH) trial was a feasibility trial that randomised 24
patients to receive intravenous tranexamic acid or placebo. Arumugam et al. (Arumugam A, Rahman NAA,
Theophilus SC, Shariffudin A, Abdullah JM. Tranexamic acid as antifibrinolytic agent in non traumatic
intracerebral hemorrhages. Malays J Med Sci 2015;22:62–71) was a single-centre, single-blind RCT that
allocated 30 patients to treatment with intravenous tranexamic acid or placebo. Two recent systematic
reviews concluded that there is no evidence for tranexamic acid treatment in SICH, although there are six
ongoing RCTs, including the TICH-2 trial.
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Objectives
The primary objective of the trial was to assess whether or not tranexamic acid is safe and improves the
functional status (i.e. reduces death and dependency) of patients after SICH. The secondary objective was
to assess the effect of tranexamic acid on secondary outcomes: clinical outcomes (disability, quality of life,
mood, cognition), safety outcomes, costs and radiological efficacy.
Methods
The TICH-2 study was an international, double-blind, randomised, placebo-controlled Phase 3 trial. The trial
included adult patients (aged ≥ 18 years) with SICH presenting within 8 hours of symptoms onset. Exclusion
criteria were ICH secondary to anticoagulation, thrombolysis, trauma or a known underlying structural
abnormality; patients for whom tranexamic acid was contraindicated; prestroke dependence (i.e. patients
with a modified Rankin Scale [mRS] score of > 4); a life expectancy of < 3 months; and a Glasgow Coma
Scale (GCS) score of < 5. Patients were recruited by investigators from acute stroke services in 124 hospitals
in 12 countries. Ethics approval was obtained in each site and country prior to the commencement of the
study. The study was designed to be performed in two phases, an 18-month start-up phase (with the aims to
activate 30 centres and to recruit a minimum of 300 participants) and then a main phase (with 120 centres
and to recruit to a total of 2000 participants), with no break in recruitment between the two phases, as the
prespecified stopping criteria were not met.
Investigators obtained written informed consent from each participant if they had the capacity to provide it.
If participants could not give consent, a relative or representative gave proxy consent. When consent was
deferred or given by a proxy, we informed the participant about the trial as soon as possible and sought
their consent for ongoing follow-up.
Participants were randomised centrally using a secure internet site in real time. Randomisation involved
stratification by country and minimisation on key prognostic factors: age, sex, time since onset, systolic
blood pressure (SBP), stroke severity [as measured using the National Institutes of Health Stroke Scale
(NIHSS)], presence of intraventricular haemorrhage (IVH) and known history of antiplatelet treatment
used immediately prior to stroke onset. Participants were assigned to receive either an intravenous 1-g
tranexamic acid loading dose in 100 ml of 0.9% normal saline infused over 10 minutes, followed by
another 1 g of intravenous tranexamic acid in 250 ml of 0.9% normal saline that was infused over 8 hours,
or a matching placebo (i.e. 0.9% normal saline), which was administered with an identical regimen.
Individual masked treatment packs comprised four 5-ml glass ampoules containing either 500 mg of
tranexamic acid or 0.9% sodium chloride. Packs were made identical in appearance and were labelled
with a unique pack number. The randomisation system allocated each participant a unique number
corresponding to a treatment pack containing either tranexamic acid or placebo. Treatment allocation was
concealed from all staff and patients involved in the trial.
At randomisation, investigators recorded participants’ age, sex and medical history, as well as their
assessment of ICH location, presence of IVH, whether or not advanced imaging had been performed and,
if applicable, presence of spot sign. Investigators assessed prestroke dependence with the mRS, and stroke
severity using the NIHSS and GCS. Participants were reviewed at days 2 and 7 and on the day of death or
hospital discharge, whichever came first, to gather information on clinical assessment (NIHSS), the process-
of-care measures (e.g. blood pressure-lowering treatment, neurosurgical intervention), and discharge date
and destination (e.g. home or institution).
Central assessors who were trained and certified in administration of the mRS and masked to treatment
allocation carried out the final follow-up at 90 days by telephone from the co-ordinating centre in each
country. If the participant or carer could not be contacted, they received a questionnaire by post, covering
the same outcome measures.
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Brain imaging by computed tomography (CT) scanning was done as part of routine care before enrolment; a
second research CT scan was done 24 hours after treatment to assess haematoma expansion. When multiple
scans were done, the scan closest to 24 hours after randomisation was used. Central independent expert
assessors, who were masked to treatment assignment, assessed CT scans for the location of the ICH using
a web-based adjudication system. Semi-automated segmentation of the ICH was done on Digital Imaging
and Communications in Medicine [DICOM®; Medical Imaging & Technology Alliance (MITA), Arlington, VA,
USA]-compliant images to give ICH volumes. The user-guided three-dimensional active contour tool in the
itk-SNAP software (version 3.6; www.itksnap.org/pmwiki/pmwiki.php, accessed 3 May 2019) was used for
segmentation and one of three assessors did, as required, manual editing. All assessments were masked to
treatment assignment. Haematoma expansion was defined as an absolute increase of > 6 ml or a relative
growth of > 33%.
The primary outcome was functional status at day 90, as assessed with the mRS, which was administered
by telephone or by postal questionnaire, and was masked to treatment allocation. Secondary outcomes
included:
l neurological impairment at day 7 or discharge (whichever came first), as assessed by the NIHSS
l health-related quality of life, as measured by the EuroQoL-5 Dimensions (EQ-5D) health-utility status
and visual analogue scale
l activities of daily living, as assessed according to the Barthel index
l cognition, as assessed via the Telephone Interview Cognitive Score – Modified (TICS-M), and verbal
fluency
l mood, as assessed by the Zung Depression Scale
l costs (length of hospital stay and discharge destination)
l radiological efficacy [change in haematoma volume (HV) from baseline to 24 hours and haematoma
expansion].
Prespecified safety outcomes were death, venous thromboembolism, ischaemic events (stroke, transient
ischaemic attack, myocardial infarction (MI), acute coronary syndrome, peripheral artery disease) and
seizures. These safety outcomes were reported up to day 90, along with all serious adverse events (SAEs)
in the first 7 days. Safety outcomes and SAEs were independently adjudicated and masked to treatment
assignment. Serious adverse events were categorised in accordance with the Medical Dictionary for
Regulatory Authorities (MedDRA).
Results
In total, 2325 participants were recruited from 124 hospitals in 12 countries over 55 months, from which
1161 participants were randomly assigned to receive tranexamic acid (n = 1161) or placebo (n = 1164).
Most participants were recruited in the UK (1910, 82%). The mean age of participants was 68.9 years
[standard deviation (SD) 13.8 years] and 1301 (56%) participants were male. The median time from stroke
onset to randomisation was 3.6 hours [interquartile range (IQR) 2.6–5.0 hours] and 833 (36%) participants
were recruited within 3 hours. The mean baseline SBP was 173 mmHg (SD 27.5 mmHg) and the mean
baseline diastolic blood pressure was 93 mmHg (18.4 mmHg). A total of 1371 (59%) participants had
a haematoma that was supratentorial deep, whereas 738 (32%) participants had one that was
supratentorial lobar; 745 (32%) participants had IVH. The mean HV was 24.0 ml (SD 27.2 ml) and the
median HV was 14.1 ml (IQR 5.9–32.4 ml). Contrast-enhanced imaging in the form of computed
tomography angiography (CTA) scanning was done in 249 (11%) participants. Of these individuals, 24
(20%) of 121 in the tranexamic acid group and 32 (25%) of 128 in the placebo group were spot positive.
Treatment groups were well balanced at baseline.
The primary outcome of mRS score, at day 90, was assessed in 2307 (99%) of 2325 participants; nine
(< 1%) were lost to follow-up and nine (< 1%) withdrew from follow-up. There was no difference in the
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distribution in the mRS score at day 90 after adjustment for stratification and minimisation criteria, with an
aOR of 0.88 (95% CI 0.76 to 1.03; p = 0.11). A formal goodness-of-fit test showed no evidence that the
proportional odds assumption was violated (p = 0.97). In a sensitivity analysis, no difference was detected
between the trial groups in the proportion of participants who were dead or dependent at day 90
(i.e. a mRS score of > 3) and the aOR was 0.82 (95% CI 0.65 to 1.03; p = 0.08). In the prespecified subgroup
analysis, the only significant interaction was between mRS score and baseline SBP (interaction p = 0.019).
Participants in the tranexamic acid group, with a baseline SBP ≤ 170mmHg had a favourable shift in mRS
score, compared with those participants with a baseline SBP > 170 mmHg. There was no heterogeneity
of treatment effect by time of administration, whether dichotomised as < 3 hours versus ≥ 3 hours
(interaction p = 0.75) or as < 4.5 hours versus ≥ 4.5 hours (interaction p = 0.28) or when analysed as a
continuous variable (aOR 0.98, 95% CI 0.90–1.07; p = 0.69).
Fewer participants in the tranexamic acid group had haematoma expansion at day 2 [265 (25%) of 1054
participants] than in the placebo group [304 (29%) of 1058 participants; aOR 0.80, 95% CI 0.66 to 0.98;
p = 0.030]. The mean increase in HV from baseline to 24 hours was also smaller in the tranexamic acid
group [3.72 ml (SD 15.9 ml)] than in the placebo group [4.90 ml (SD 16.0 ml); adjusted mean difference
(aMD) –1.37 ml, 95% CI –2.71 to –0.04 ml; p = 0.043].
Neurological impairment (as assessed via the mean NIHSS score) at day 7 did not differ between the
tranexamic acid group and the placebo group (aMD –0.43, 95% CI –0.94 to 0.09; p = 0.10).
There were no significant differences in any of the day 90 functional outcomes between treatment groups,
that is, activities of daily living, mood, cognition or quality of life. Length of hospital stay and discharge
disposition did not differ between treatment groups.
By day 7, fewer patients had died in the tranexamic acid group [101 (9%) of 1161 participants] than in the
placebo group [123 (11%) of 1164 participants]. However, the number of deaths by day 90 did not differ
between the tranexamic acid group [250 (22%) patients] and the placebo group [249 (21%) patients].
Survival did not differ between the treatment groups over 90 days (adjusted hazard ratio 0.92, 95% CI
0.77 to 1.10; p = 0.37).
Participants in the tranexamic acid group had fewer predefined safety outcomes and SAEs than those in
the placebo group at days 2 [379 (33%) patients vs. 417 (36%) patients; p = 0.027], 7 [456 (39%) vs. 497
(43%); p = 0.020], and at 90 days [521 (45%) vs. 556 (48%); p = 0.039]. There was no increase in venous
thromboembolic events [39 (3%) patients in the tranexamic acid group vs. 37 (3%) in the placebo group;
p = 0.98], seizures or arterial occlusions (MI, acute coronary syndrome or peripheral arterial occlusion) in
the tranexamic acid group compared with the placebo group.
Conclusions
Tranexamic acid did not have a significant benefit on functional status at day 90, although potential benefits
were seen with significant modest reductions in haematoma expansion, early death and SAEs. The observed
effect size was smaller than anticipated and is compatible with a lack of efficacy or the presence of a smaller
treatment effect than expected.
Implications for health care
Based on current evidence, tranexamic acid cannot be recommended for routine treatment of patients
with SICH. Tranexamic acid is inexpensive, easy to administer, seems to be safe and is widely available,
so even a modest treatment effect could have an important impact on a global scale.
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Recommendations for research
Although there is insufficient evidence to support the routine use of tranexamic acid in clinical practice for
SICH, the results do not exclude a modest beneficial effect. The reductions in haematoma expansion and
early deaths may reflect an antifibrinolytic effect and are promising, but further large randomised trials
are needed to confirm or refute a clinically significant treatment effect. Future research should focus on
enrolling participants earlier after ICH onset and investigate which subgroups of patients are most likely
to benefit.
Trial registration
The trial is registered as ISRCTN93732214.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research; Pragmatic Trials, UK; and the Swiss Heart Foundation in Switzerland.
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Chapter 1 Introduction
Sections of text of this report are reproduced from Sprigg et al.1 This is an Open Access article distributedin accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Scientific background
Haemorrhagic stroke
Haemorrhagic stroke or intracerebral haemorrhage (ICH), caused by bleeding in the brain, can be
devastating and is a common cause of death and disability, both in the UK and worldwide.2 Despite the
development of effective treatments for ischaemic stroke (thrombolysis, mechanical thrombectomy, aspirin,
hemicraniectomy), there is no proven effective treatment for spontaneous ICH (SICH).
Haematoma expansion
Outcome after ICH is closely related to whether brain bleeding expands after onset, so-called haematoma
expansion, or whether rebleeding occurs; both are associated with a bad outcome (i.e. death and disability).3,4
Contrast extravasation during contrast-enhanced computed tomography (CT) and CT angiography (CTA),
known as the spot sign, have been shown to predict haematoma expansion.5 Nevertheless, there is currently
wide variation in the use of these techniques in routine clinical practice.
Haematoma expansion is related to both haemostatic factors and blood pressure. Furthermore, haematoma
volume (HV) can be reduced surgically; all these approaches are potential targets for treatment of ICH.
Intensive blood pressure treatment
Lowering blood pressure in patients with ICH is a potential therapeutic option to limit haematoma
expansion and improve outcome. The Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage
Trial (INTERACT) assessed intensive blood pressure treatment in 404 ICH patients. The study showed that
aggressively lowering blood pressure appeared safe and may limit haematoma expansion, but did not
change outcome.6 In the INTERACT-2 trial, the largest intervention trial of SICH that involved 2839
patients, intensive blood pressure lowering to a systolic blood pressure (SBP) of < 140 mmHg is safe and
resulted in a significant shift in ordinal analysis of the modified Rankin Scale (mRS) score, although there
was no significant improvement in primary outcome of death and disability (i.e. a mRS score of 3–6).7
In view of this result, the European Stroke Organisation’s (ESO’s) 2014 guideline and the American Heart
Association/American Stroke Association’s (AHA/ASA’s) 2015 guideline suggest that lowering blood
pressure to a SBP of 140 mmHg is safe and may have a beneficial effect on functional outcome.8,9
The most recent development of blood pressure treatment in SICH is the Antihypertensive Treatment of
Acute Cerebral Hemorrhage II (ATACH II) trial, which was stopped early in view of futility after recruiting
1000 patients. There was no significant difference in death or dependency between the intensive and
guideline treatment groups. In addition, there were higher renal adverse events in those participants treated
with intensive blood pressure reduction.10 There are several potential reasons why the ATACH II trial had
different findings compared with previous trials. Patients in the trial received intravenous antihypertensive
medication pre randomisation to ensure compliance with guidelines. Furthermore, the blood pressure
reduction was much larger than seen in previous trials; from a baseline SBP of approximately 200 mmHg,
the intensive arm achieved a mean minimum SBP of 129 mmHg, whereas the standard treatment arm
attained a mean minimum SBP of 141 mmHg. In contrast, the baseline blood pressure was approximately
179 mmHg in the INTERACT-2 trial, with the intensive and standard treatment groups achieving a SBP of
150 mmHg and 164 mmHg at 1 hour post randomisation, respectively. These results suggest that the
degree of blood pressure reduction in the standard arm of the ATACH II trial is similar to the intensive arm
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of the INTERACT-2 trial.11 In addition, all patients in the ATACH II trial were treated with intravenous
nicardipine, which has a weak antiplatelet effect, possibly negating the benefit achieved by blood pressure
reduction.11,12 The UK’s 2016 national clinical guideline for stroke recommends lowering blood pressure to a
SBP of 140 mmHg, whereas the 2017 American guideline suggests that lowering blood pressure to a SBP of
< 140 mmHg may be harmful.13,14
Surgery for intracerebral haemorrhage
The current role of surgery is limited to patients with cerebellar haematoma. Posterior decompression in
patients with cerebellar haematoma of > 3 cm and that result in hydrocephalus or brainstem compression
is life-saving.15,16 In addition, in ICH complicated with hydrocephalus, the placement of an external
ventricular drain lowers intracranial pressure and may reduce mortality.17
The role of routine surgery in patients with supratentorial haematoma is unclear. The international Surgical
Trial in IntraCerebral Haemorrhage (STICH) was a prospective, open-label, blinded, end point, randomised
controlled trial (RCT) that randomised 1033 patients with ICH to early surgical haematoma evacuation and
initial conservative treatment. There was no significant difference in outcome between the two trial groups.18
This may be because patients were recruited only when the surgeon was in equipoise and time to surgery
was delayed (mean time 30 hours) and, thus, surgery was unlikely to be able to limit haematoma expansion.
However, a subgroup analysis of the trial showed that patients with superficial haematoma (i.e. < 1 cm from
the surface) benefited from early surgery. The trial also found that patients with a poor initial Glasgow Coma
Scale (GCS) score of < 8 and intraventricular haemorrhage (IVH) had poor outcomes despite surgery.18
The subsequent early surgery versus initial conservative treatment in patients with spontaneous supratentorial
lobar ICHs (STICH II) trial randomised 601 patients with superficial lobar haematomas, with a HV of 10–100 ml
and without intraventricular extension to undergo early surgery or initial conservative management. There was
an absolute reduction in mortality of 6% and a 4% increase in favourable outcome in the early surgery arm,
although the difference was not statistically significant.19 One reason that may explain this neutral result is
that the trial recruited patients who were conscious or mildly confused who might not have benefited from
surgery. Patients with poorer GCS scores of between 9 and 12 benefited from early surgery.19 A meta-analysis
including STICH II and 14 other trials (3366 patients), concluded that there was an overall benefit for early
surgery [odds ratio (OR) 0.74, 95% confidence interval (CI) 0.64 to 0.86].19 However, the meta-analysis should
be interpreted with caution, as there was significant heterogeneity in the trials. It is unclear whether or not the
surgical intervention benefited certain subgroups of patients. The current ESO guideline8 does not recommend
routine surgery for supratentorial haematoma, although early surgery may be considered in patients with
GCS scores of 9–12. Similarly the AHA/ASA guideline does not recommend routine surgery for supratentorial
haematoma except in patients who are deteriorating.9
Haemostatic therapy
In anticoagulant-related ICH, haemostatic therapy plays an important role. In vitamin K antagonist-related
ICH, the four-factor prothrombin complex concentrate (4F-PCC) normalised the international normalised
ratio (INR) to < 1.2 within 3 hours in 67% of patients compared with only 9% of patients with fresh-frozen
plasma (FFP).20 Where 4F-PCC is not available, FFP can be given as an alternative. In addition, intravenous
vitamin K should be given. In ICH related to direct oral anticoagulants (DOACs; e.g. dabigatran, rivaroxaban,
apixaban, edoxaban), reversal agents are now available. Idarucizumab is a specific reversal agent for the
direct thrombin inhibitor, dabigatran.21 Idarucizumab normalises diluted thrombin time and ecarin and
thrombin clotting time within 15 minutes in almost 100% of patients.21 Andexanet alfa, a reversal agent for
direct (rivaroxaban, apixaban, edoxaban) and indirect factor Xa inhibitor (enoxaparin), was found to reverse
the anti-Xa activities of rivaroxaban and apixaban within minutes of administration. Andexanet alfa was
tested in a single-arm study among 67 patients who had intracranial and other major bleeding secondary
to rivaroxaban, apixaban and enoxaparin. Effective haemostasis was achieved in 79% of the patients within
12 hours. However, 18% (12/67) of the patients had thromboembolic events.22 Andexanet alfa was
approved as a reversal agent by the US Food and Drug Administration in May 2018. The role of an
antifibrinolytic agent, that is, tranexamic acid in DOAC-related ICH, is being examined.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
The role of haemostatic therapy in ICH not related to anticoagulant is less clear. The most widely studied
agent is recombinant factor VIIa (rFVIIa). In a Phase IIb trial with 399 patients, rFVIIa restricted haematoma
expansion, improved functional outcome and reduced mortality despite a significant increase in arterial
thromboembolic events.23 However in a larger Phase III study with 841 patients, rFVIIa had no effect on
functional outcome or mortality despite restricting haematoma expansion.24 A meta-analysis comparing
blood clotting factors versus placebo or open control, including 1480 patients from seven RCTs, found no
significant benefit on mortality, or death or dependency.25 There was a trend to improved outcome which
was offset by an increase in thromboembolic events. Two RCTs recruited only ICH patients with positive
CTA spot sign, that is, those patients at risk of haematoma expansion and most likely to benefit from
rFVIIa.26,27 However, the trials were stopped as a result of poor recruitment and the data have not yet been
published, except in abstract form.28
Platelet transfusion in antiplatelet-related ICH was found to be harmful in the platelet transfusion versus
standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy
(PATCH) trial. The odds of death or dependence at 3 months were higher in the platelet transfusion group
than in the standard care group [adjusted common OR 2.05, 95% CI 1.18 to 3.56; p = 0.011].29
Tranexamic acid
Tranexamic acid is a licensed antifibrinolytic drug that can be administered intravenously or orally and is used
in a number of bleeding conditions to reduce bleeding. In the Clinical Randomisation of an Antifibrinolytic
in Significant Haemorrhage – 2 (CRASH-2) trial involving 20,211 patients with major bleeding following
trauma, tranexamic acid significantly reduced mortality (OR 0.91, 95% CI 0.85 to 0.97), with no increase in
vascular occlusive events. Treatment was most effective when given rapidly; delayed administration was
associated with a lack of efficacy and potential harm. In a subgroup analysis of patients with traumatic ICH,
tranexamic acid showed a non-significant trend to reduced mortality (OR 0.47, 95% CI 0.21 to 1.04), and
death or dependency (OR 0.66, 95% CI 0.32 to1.36). However, patients in the CRASH-2 trial were younger
and had fewer comorbidities than those with SICH. In another RCT in traumatic ICH, tranexamic acid
reduced death (OR 0.69, 95% CI 0.35 to 1.39) and death or dependency (0.76, 95% CI 0.46 to 1.27),
without an increase in thromboembolic events. A meta-analysis of tranexamic acid in traumatic intracranial
haemorrhage showed that it was associated with a significant reduction in subsequent intracranial bleeding
and a larger trial is ongoing.30,31
In the WOrld Maternal ANtifibrinolytic (WOMAN) trial, involving 20,060 women, tranexamic acid reduced
death due to bleeding in women with postpartum haemorrhage [risk ratio (RR) 0.81, 95% CI 0.65 to 1.00;
p = 0.045], with the effect greatest in women given treatment within 3 hours of childbirth (RR 0.69, 95% CI
0.52 to 0.91; p = 0.008).32 The need to administer tranexamic acid immediately in bleeding conditions was
again highlighted in an individual patient data meta-analysis combining data from the CRASH-2 and WOMAN
trials. Immediate treatment improved survival by > 70% (OR 1.72, 95% CI 1.42 to 2.10; p < 0.0001) and the
survival benefit decreased by 10% for every 15 minutes of treatment delay until 3 hours, after which there
was no benefit.33
Tranexamic acid has been tested in aneurysmal subarachnoid haemorrhage, where it reduced the risk of
rebleeding at the expense of increased risk of cerebral ischaemia.34 However, many of the trials of tranexamic
acid in subarachnoid haemorrhage involved giving high doses of up to 6 g per day for a prolonged duration
of 3–6 weeks, and this could have accounted for the increased number of ischaemic events.34
Tranexamic acid has been found to restrict haematoma expansion in acute SICH in a small non-randomised
study, although this study did not report on safety.35 In another small study (n = 156), rapid administration
of a bolus of tranexamic acid within 24 hours of stroke was observed to reduce haematoma expansion
(17.5% vs. 4.3%).36 In this study, tranexamic acid was given in combination with intensive blood pressure
control, suggesting that it may be possible to combine haemostatic and haemodynamic approaches.
The authors subsequently reported a study of an additional 95 patients treated with a rapid infusion of
tranexamic acid with haematoma expansion occurring in 4.2% of these patients.37
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Systematic review of randomised controlled trials of tranexamic acid in intracerebral
haemorrhage
The Cochrane Stroke Trials Register, the Cochrane Central Register of Controlled Trials, MEDLINE (via Ovid)
and EMBASE (via Ovid) were searched from inception to 27 November 2017 for RCTs of antifibrinolytics
and tranexamic acid. The search terms were published previously.25 In November 2017, to identify further
published, ongoing and unpublished RCTs, bibliographies were scanned and international registers of clinical
trials were searched for relevant articles. Trials published in all languages were searched. The quality of the
evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation
(GRADE) approach. Two small RCTs of tranexamic acid, with a total of 54 participants, were found with no
clear evidence of benefit or harm associated with tranexamic acid.38,39 Therefore, the systematic review
concluded that there is a lack of evidence for the use of tranexamic acid in SICH. At the time of publication,
five further RCTs are ongoing.25,40
Rationale for trial
Haematoma expansion is a not uncommon complication of ICH and is associated with devastating
consequences of early death and severe disability in those who survive. There is no effective drug treatment
to prevent haematoma expansion. Tranexamic acid, an antifibrinolytic drug, is effective at reducing bleeding
and death due to bleeding in other conditions. Tranexamic acid is widely available, affordable and appears
to be safe in studies in other bleeding conditions conducted to date. The rationale for this study was to test
the safety and efficacy of tranexamic acid in ICH, the hypothesis being that tranexamic acid will prevent
haematoma expansion and reduce death and disability after ICH.
INTRODUCTION
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Chapter 2 Methods
Objectives
Purpose
To assess in a pragmatic Phase III prospective double-blind randomised placebo-controlled trial whether
tranexamic acid is safe and reduces death or dependency after SICH. The results will determine whether or
not tranexamic acid should be used to treat SICH, which currently has no proven therapy.
Primary objective
To assess whether or not tranexamic acid is safe and improves functional status (i.e. reduces death and
dependency) after SICH.
Secondary objectives
To assess the effect of tranexamic acid on secondary outcomes: clinical outcomes, safety outcomes, costs
and radiological efficacy.
Design
The Tranexamic acid in IntraCerebral Haemorrhage 2 (TICH-2) study was an international, double-blind,
randomised, placebo-controlled, parallel-group, Phase III trial performed in two phases: an 18-month start-up
phase (with an aim to activate 30 centres and recruit a minimum of 300 participants) and then a main
phase (with 120 centres and to recruit to a total of 2000 participants). There was no break in recruitment as
the trial proceeded from the start-up phase to the main phase because the stopping criteria were not met.
Participants were enrolled by investigators from acute stroke units at 124 hospital sites in 12 countries:
Denmark, Georgia, Hungary, Ireland, Italy, Malaysia, Poland, Spain, Sweden, Switzerland, Turkey and the
UK. Ethics approval was obtained in each site and country prior to commencement of the study. The trial
was adopted in the UK by the National Institute for Health Research Clinical Research Network and
registered with the International Standard Randomised Controlled Trial Number (ISRCTN) Registry as
ISRCTN93732214. The full TICH-2 trial protocol41 and statistical plan42 have been published.
Study settings
The study was set in acute stroke units at 124 hospitals in 12 countries (as detailed in Design). A full listing
of sites and investigators can be found in Report Supplementary Material 1.
Participants
Inclusion criteria
Adult patients (aged ≥ 18 years) with acute SICH within 8 hours of stroke onset were included in the
study. (Where stroke onset time is unknown, the time of when last known well was used.)
Exclusion criteria
Patients with ICH secondary to anticoagulation, thrombolysis or known underlying structural abnormality,
such as arterial venous malformation, aneurysm, tumour, trauma, venous thrombosis as cause for the
ICH, were excluded. Note that it was not necessary for investigators to exclude underlying structural
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abnormality prior to enrolment, but where an underlying structural abnormality was already known, these
patients would not be recruited.
Other exclusion criteria were patients for whom tranexamic acid is thought to be contraindicated, patients
with premorbid dependency (i.e. a mRS score of > 4), prestroke life expectancy < 3 months (e.g. advanced
metastatic cancer), a GCS score of < 5, female patients of childbearing potential either pregnant or
breastfeeding at randomisation, geographical or other factors that prohibited follow-up at 90 days (e.g. no
fixed address or telephone contact number or overseas visitor) and participation in another drug or devices
trial concurrently, with the exception of the secondary prevention trial, REstart or STop Antithrombolics
Randomised Trial (RESTART).
Data collected at baseline
Investigators recorded the participants’ age, sex, ethnic group, medical history and whether or not they
were taking antiplatelet agents, as well as their assessment of ICH location, IVH, spot sign and blood
pressure. Investigators assessed prestroke dependence with the mRS, and stroke severity using the National
Institutes of Health Stroke Scale (NIHSS) and GCS.
Interventions
The intervention, tranexamic acid, was given intravenously as a 1-g loading dose in 100 ml of 0.9% normal
saline infused over 10 minutes, followed by another 1 g in 250 ml of 0.9% normal saline, which was infused
over 8 hours. The comparator was a matching placebo (i.e. 0.9% normal saline), administered with an
identical regimen.
The dosing regimen selected (1-g bolus and 1-g infusion) was chosen to achieve plasma concentrations
sufficient to inhibit fibrinolysis. Studies in cardiac surgery have shown that use of a dose > 10 mg/kg bolus
and 1 mg/kg infusion does not provide any additional haemostatic benefit.43 In the emergency situation,
administration of a fixed dose is more practicable and the fixed dose chosen is efficacious for patients
weighing > 100 kg and it is safe for patients weighing < 50 kg. The short duration of treatment allows for
the full effect of tranexamic acid on the immediate risk of haematoma expansion without extending too
far into the acute phase response seen after stroke.
Randomisation
All participants eligible for inclusion were randomised centrally using a secure internet site in real time.
Randomisation involved stratification by country and minimisation on key prognostic factors: age; sex;
time since onset; SBP; stroke severity (as assessed via the NIHSS); presence of IVH; and known history
of antiplatelet treatment used immediately prior to stroke onset. This approach ensured concealment
of allocation, minimises differences in key baseline prognostic variables, and slightly improves statistical
power.
Randomisation allocated a number corresponding to a treatment pack and the participants received
treatment from the allocated numbered pack.
In the event of computer failure (e.g. server failure), investigators would follow the working practice document
for computer system disaster recovery, which will allow the participant to be randomised manually following a
standardised operating procedure.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Blinding
Clinicians, patients and outcome assessors (i.e. research nurse and radiologist) were blind to treatment
allocation. In general, there should be no need to unblind the allocated treatment. If some contraindication
to antifibrinolytic therapy developed after randomisation (e.g. clinical evidence of thrombosis), the trial
treatment would simply be stopped. Unblinding was to be done only in those rare cases when the doctor
believed that clinical management depended importantly on the knowledge of whether or not the patient
received antifibrinolytic or placebo. For those few patients for whom urgent unblinding was considered
necessary, the emergency telephone number was telephoned, giving the name of the doctor authorising
unblinding and the treatment pack number. The caller was then told whether the patient received
antifibrinolytic or placebo. The rate of unblinding was monitored and audited.
In the event of breaking the treatment code, this was recorded as part of managing a serious adverse event
(SAE; see Chapter 2, Methods, Secondary outcomes, Safety for more details) and such actions were reported
in a timely manner. The chief investigator (delegated the sponsor’s responsibilities) was informed immediately
(within 24 hours) of any SAEs and determined seriousness and causality in conjunction with any treating
medical practitioners.
Adherence
Adherence was assessed by examining the participant’s drug chart and recording the trial treatment
administered at day 2 (i.e. whether or not all treatment was given, the time and date of the two doses and
any other comments). Adherence was verified by both the central review of the drug chart and pharmacies
recording returns of residual or unused trial medications.
Assessments after randomisation
Participants were reviewed at days 2 and 7, and on the day of death or hospital discharge, whichever
came first, to gather information on clinical assessment (i.e. the NIHSS score), the process-of-care measures
(e.g. blood-pressure-lowering treatment, neurosurgical intervention) and discharge date and destination
(e.g. home or institution). A second research CT scan was carried out after 24 hours of treatment to assess
haematoma expansion.
The central assessors, who were trained and certified in administration of the mRS and masked to treatment
allocation, carried out the final follow-up at 90 days by telephone from the co-ordinating centre in each
country. If the participant or carer could not be contacted, they received a questionnaire covering the same
outcome measures by post.
Primary efficacy outcome
Functional status, death or dependency (ordinal shift on the mRS) at day 90 was compared between
tranexamic acid and placebo by intention to treat using ordinal logistic regression (OLR), with adjustment
for stratification and minimisation factors. The assumption of proportional odds was tested using the
likelihood ratio test.
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Secondary outcomes
Clinical
Clinical outcomes
Neurological impairment was measured (using the NIHSS44) at day 7 (or discharge if sooner).
Day 90 outcomes
The outcomes measured at day 90 were disability (using the Barthel index45), dependency (using the mRS46),
quality of life [using the EuroQol-5 Dimensions (EQ-5D) questionnaire and the EuroQol Visual Analogue
Scale (EQ-VAS47)], cognition [using the Telephone Interview Cognitive Score – Modified (TICS-M)
questionnaire48] and mood (using the Zung Depression Scale49).
Costs
Cost outcomes included length of stay in hospital, readmission and institutionalisation.
Radiological
Radiological outcomes included relative and absolute haematoma growth and haematoma expansion.
Safety
Safety outcomes included:
l death (cause)
l venous thromboembolism (VTE)
l vascular occlusive events [stroke/transient ischaemic attack/myocardial infarction (MI)/peripheral
artery disease]
l seizures
l SAEs in first 7 days.
In addition, any safety interaction between the treatment effect and time to randomisation was assessed.
Definitions of evidence required for adjudication of safety outcomes can be found in Appendix 1.
Study oversight
The trial was overseen by a Trial Steering Committee (TSC) and an International Advisory Committee
comprising each national co-ordinator. A Trial Management Committee, based at the Stroke Trials Unit
in Nottingham, UK, was responsible for the day-to-day conduct of the trial. Study data were collected,
monitored and analysed in Nottingham. The trial was performed according to the principles of good
clinical practice and the Declaration of Helsinki.50
Data Safety Monitoring Committee
An independent Data Safety Monitoring Committee (DSMC) was established. The DSMC received safety
reports every 6 months, and performed a total of six unblinded reviews of efficacy and safety data. The
DSMC performed a formal interim analysis after 818 participants had been recruited (comprising both trial
phases) and followed up at 90 days.
A DSMC charter was prepared containing information on the membership, terms and conditions and full
details of the stopping guidelines. The DSMC reported its assessment to the independent chairperson of
the TSC, who reported to the National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) programme.
METHODS
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Missing data
Any missing data were reported. For participants to have been included in the primary analysis they must
have had their mRS score at day 90 recorded along with values for all of the minimisation criteria; if not,
then they were excluded from the analysis. To include as many of the participants as possible, any missing
minimisation criteria were backfilled from their randomisation form. The first step was to contact the
recruiting centre and ask if it had this information, if not then imputation was used. If any of the individual
NIHSS measures were missing, then the highest risk value was imputed to ensure that a total NIHSS score
could be calculated for each participant. If the history of antiplatelet treatment was not known and could
not be found, then the highest risk value was imputed, as would have been used in the randomisation
process. Participants who died before day 90 were given death scores for outcome measures: a mRS score
of 6, an EQ-5D score of 0, a Barthel Index of –5, an EQ-VAS of –1, a TICS-M score of –1, an Animal Naming
Test score of –1 and a Zung Depression Scale score of 102. Missing outcome data from other follow-ups
were excluded from any analyses. If a participant withdrew consent, no further information was collected;
however, data collected thus far from follow-up assessments were used for any of the analyses.
Statistical analysis
Statistical analyses were performed according to the published statistical analysis plan by Katie Flaherty and
Polly Scutt, with oversight by Stuart J Pocock using SAS® software (version 9.4; SAS Institute Inc., Cary,
NC, USA). Analyses were by intention to treat for all comparisons. Data shown are number (%), median
[interquartile range (IQR)], mean [standard deviation (SD)] and odds ratio (95% CIs).
Death or dependency (ordinal shift on mRS) at day 90 was analysed between tranexamic acid and placebo by
intention to treat using OLR, with adjustment for stratification and minimisation factors, which include: age
(< 70 years, ≥ 70 years), sex (female, male), time from stroke onset to randomisation (< 3 hours, ≥ 3 hours),
mean SBP (< 170mmHg, ≥ 170mmHg), stroke severity (NIHSS score of < 15, ≥ 15), presence of IVH (no,
yes), known history of antiplatelet therapy used prior to stroke onset (no, yes) and country. As a sensitivity
analysis, the primary outcome was also analysed unadjusted and as a binary outcome (a mRS score of > 3
vs. a mRS score of ≤ 3). The heterogeneity of the treatment effect on the primary outcome was assessed in
prespecified subgroups and by adding an interaction term into the adjusted OLR model.
For secondary outcomes, binary logistic regression will be used for binary outcomes, including death, SAEs
and thromboembolic events. Multiple linear regression will be used for continuous measures, including
haematoma expansion. Wilcoxon rank-sum test will be used for continuous measures, which are not normally
distributed, including the Barthel Index. Cox proportional hazards regression will be used for time-to-event
analyses, including death. All regression analyses will be performed with adjustment for stratification and
minimisation factors, as stated above. To review the overall trend of the data a global test (i.e. a Wei–Lachin
test) was used on a combination of outcome measures. The impact of tranexamic acid on quality of life was
assessed using the EuroQoL measure. Comparisons between the treatments will be performed in prespecified
subgroups, the low-risk groups are given first in the brackets, as follows; minimisation criteria; CTA (yes, no);
haematoma location (deep, lobar); and ethnicity (other, white).
The subgroup analysis did not constitute the primary analysis and, thus, has not informed the sample size
calculation. The interpretation of any subgroup effect was based on interaction tests (i.e. evidence of
differential treatment effects in the different subgroups) and there was no adjustment for multiple testing.
The minimisation criteria were chosen and included in the subgroup analysis, as they are independent
prognostic indicators of ICH.
The nominal level of significance for all analyses was a p-value of < 0.05. No adjustment was made for
multiplicity of testing.
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Sample size
The null hypothesis (H0) is that tranexamic acid does not alter death or dependency in participants with
acute primary ICH. The alternative hypothesis (HA) is that death or dependency differs between those
participants randomised to tranexamic acid and those randomised to saline. A total sample size of 2000
(1000 per group) participants with acute primary ICH is required, assuming:
l an overall significance of (alpha) = 0.05
l a power of (1 – beta) = 0.90
l a distribution in mRS score (mRS 0 = 4%, 1 = 17%, 2 = 16%, 3 = 19%, 4 = 24%, 5 = 7% and 6 (death)
= 13%; based on data from participants with primary ICH in the Efficacy of Nitric Oxide in Stroke
(ENOS) trial
l an ordinal OR of 0.79
l increases due to losses to follow-up of 5%
l a reduction of 20% for baseline covariate adjustment.51
In summary, a trial of 2000 participants (1700 from the main phase and 300 from the start-up phase) will
have 90% power to detect an ordinal shift of mRS outcome with an OR of 0.79.
Protecting against bias, including blinding
Numerous steps were taken to protect against bias in this double-blind RCT, with allocation concealed
from all staff throughout the study.
Neuroimaging and scan adjudication
Brain imaging by CT was done as part of routine care before enrolment; a second research CT scan was
done after 24 hours of treatment to assess haematoma expansion. When multiple scans were done, the scan
closest to 24 hours after randomisation was used. Central independent expert assessors, who were masked to
treatment assignment, assessed CT scans for the location of the ICH using a web-based adjudication system.
Semi-automated segmentation of the ICH was done on Digital Imaging and Communications in Medicine
[DICOM®; Medical Imaging & Technology Alliance (MITA), Arlington, VA, USA]-compliant images to give
ICH volumes. The user-guided three-dimensional active contour tool in the itk-SNAP software (version 3.6;
www.itksnap.org/pmwiki/pmwiki.php, accessed 3 May 2019) was used for segmentation and, as required,
one of the three assessors did manual editing. All assessments were masked to treatment assignment.
Haematoma expansion was defined as an absolute increase of > 6 ml or a relative growth of > 33%.
Sites, investigators and monitoring
Investigators were trained in trial procedures, via a site initiation teleconference, after obtaining all of the
necessary regulatory approvals. New investigators who joined the study after the site initiation training
were required to complete and pass an online training test covering the trial protocol. Monitoring of trial
data included confirmation of informed consent in all participants; source data verification; data storage
and data transfer procedures; local quality control checks and procedures, back-up and disaster recovery of
any local databases; and validation of data manipulation. The trial co-ordinator carried out monitoring of
trial data throughout the study; entries on case report forms (CRFs) were verified by inspection against the
source data. A sample of CRFs (10% as per the trial risk assessment) were checked for verification of all
entries made. In addition, the subsequent capture of the data on the trial database was checked. Where
corrections were required, a full audit trail and justification was documented.
METHODS
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Protocol amendments
During the course of the trial there was a number of amendments to the study protocol, which are detailed
in Chapter 2, Methods, Substudies. In summary, these amendments were to add a number of substudies
[i.e. a day 365 follow-up, a magnetic resonance imaging (MRI) substudy and a biomarker substudy], make
minor changes to trial documentation and allow co-enrolment to the ongoing RCT, RESTART. Full details of
protocol amendments can be found in Appendix 2.
Substudies
Three substudies were performed and will be presented elsewhere. First, an additional follow-up at day
365 was performed and, second, a MRI substudy (funded by the British Heart Foundation) was performed,
which will be presented separately. Finally, a single-centre plasma biomarker substudy examined the effect
of tranexamic acid on markers of haemostasis and inflammation.
Meta-analysis
In due course, data from TICH-2 will be added to summary and individual patient data meta-analyses in
acute stroke. This will include data being used in a Cochrane review25 and in an individual patient data
meta-analysis of all tranexamic acid effects in ICH by the Antifibrinolytics Triallists Collaboration (ATC).52
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Chapter 3 Results
Recruitment
Recruitment started on 1 March 2013 and ended on 30 September 2017, after a 12-month extension was
sought and approved to enable the trial to reach its target sample size (Table 1). This slower-than-planned
recruitment was due to delays in opening trial sites outside the UK. Subsequently, recruitment increased
and the TSC agreed that the study should exceed the target of 2000 and continue until the end of the
extension. Therefore, a total of 2325 participants (1161 randomised to tranexamic acid and 1164 to
placebo) were recruited from 124 sites in 12 countries over 55 months (Tables 1 and 2 and Figures 1–3).
There was good data completion, with nine patients lost to follow-up or withdrawn in each of the
treatment groups (see Figure 3).
Baseline data
The majority of participants were recruited in the UK (1910, 82.2%). The mean age of participants was
68.9 years (SD 13.8 years); 1301 participants (56%) were male. The median time from stroke onset to
randomisation was 3.6 hours [IQR 2.6–5.0 hours] and one-third of participants (833, 36%) were recruited
within 3 hours (Table 3). The mean baseline blood pressure was 173/93 mmHg. The majority of participants
had a haematoma that was deep and supratentorial (1371, 59.0%), with 738 (31.7%) participants having
a lobar supratentorial haematoma; one-third of participants had IVH. The mean HV was 24.0 ml (SD 27.2 ml)
and the median HV was 14.1 ml (IQR 5.9–32.4 ml). Contrast-enhanced imaging, conducted as CTA,
was performed in 249 (10.9%) of the participants. Twenty-four out of 121 (19.8%) participants in the
tranexamic acid group and 32 out of 128 (25%) in the placebo group were spot positive. Treatment groups
were well balanced at baseline.
Adherence/tranexamic acid treatment
Adherence to the allocated treatment was high, that is, 2207 (94.9%) participants received all of their
randomised treatment, whereas only 15 (0.6%) participants received no treatment. There was no difference
in adherence rates between the treatment groups. The median time from randomisation to treatment was
21 minutes (IQR 13–33 minutes) (Table 4).
TABLE 1 Recruitment summary
Recruitment
Date recruitment started 14 March 2013
Date recruitment stopped 30 September 2017
Randomisation
Number of patients randomised 2325
Number of centres that randomised patients 124
Number of countries that randomised patients 12
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TABLE 2 Recruitment by country
Country
Recruitment
Number (%) of participants
randomised
Average number of participants
randomised per month
Total number recruited 2325
UK 1910 (82.2) 32.93
Georgia 141 (6.1) 3.28
Italy 96 (4.1) 1.92
Malaysia 46 (2.0) 1.64
Switzerland 46 (2.0) 1.53
Denmark 39 (1.7) 2.17
Republic of Ireland 17 (0.7) 0.65
Hungary 9 (0.4) 0.64
Turkey 9 (0.4) 0.33
Sweden 8 (0.3) 0.29
Poland 3 (0.1) 0.19
Spain 1 (0.0) 0.06
0
500
1000
1500
2000
2500
Ja
nu
ar
y 2
01
3
Au
gu
st 
20
13
M
ar
ch
 2
01
4
Se
pt
em
be
r 2
01
4
Ap
ril
 2
01
5
Oc
to
be
r 2
01
5
M
ay
 20
16
No
ve
m
be
r 2
01
6
Ju
ne
 20
17
De
ce
m
be
r 2
01
7
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
Date
Target
Original prediction
Recruitment
Actual
FIGURE 1 Recruitment graph.
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Enrolment
Randomised
(n = 2325)
Allocation
Allocated to tranexamic acid
(n = 1161)
• Received allocated intervention, n = 1150
• Did not receive allocated intervention:
   • No treatment given, n = 9
   • Not known if treatment given, n = 2 
Day 2 assessment completed
(n = 1161)
Lost to follow-up
(n = 0) 
Died by day 2
(n = 40)
Day 7 assessment completed
(n = 1161)
Lost to follow-up
(n = 0) 
Died by day 7
(n = 101)
Analysed
(n = 1152)
Died by day 90
(n = 250)
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Died by day 7
(n = 101)
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(n = 1164)
Lost to follow-up
(n = 0) 
Died by day 2
(n = 57)
Allocated to placebo
(n = 1164)
• Received allocated intervention, n = 1157
• Did not receive allocated intervention:
   • No treatment given, n = 6
   • Not known if treatment given, n = 1 
Follow-up, day 2
Follow-up, day 7
Analysis, day 90
• Excluded from analysis:
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   • Lost to follow-up, n = 3
Analysed
(n = 1155)
Died by day 90
(n = 249) 
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FIGURE 3 Participant Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
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TABLE 3 Clinical characteristics at randomisation
Baseline variable N
Treatment group
Tranexamic acid Placebo
Patients randomised, n 1161 1164
Age (years)
Mean (SD) 2325 69.1 (13.7) 68.7 (13.9)
Sex, n (%)
Male 2325 642 (55.30) 659 (56.62)
Ethnic origin, n (%)
White 2324 986 (85.00) 992 (85.22)
Black 2324 49 (4.22) 47 (4.04)
Asian 2324 107 (9.20) 111 (9.53)
Other 2324 18 (1.55) 14 (1.20)
Country, n (%)
UK 2325 954 (82.17) 956 (82.13)
Onset to randomisation (hours)
Median (IQR) 2325 3.6 (2.6–5.1) 3.7 (2.6–5.0)
History of, n (%)
Antiplatelet therapy 2324 316 (27.24) 295 (25.34)
Statin use 2307 319 (27.69) 303 (26.23)
Previous stroke or TIA 2301 174 (15.17) 156 (13.52)
IHD 2298 110 (9.62) 92 (7.97)
Thromboembolism 2296 15 (1.31) 19 (1.65)
Hypertension 2310 700 (60.66) 721 (62.37)
Pre-stroke mRS score
Median (IQR) 2325 0.0 (0.0–1.0) 0.0 (0.0–1.0)
> 2, n (%) 2325 104 (8.96) 103 (8.85)
GCS score
Mean (SD) 2325 13.4 (2.2) 13.5 (2.1)
NIHSS score
Mean (SD) 2325 13.1 (7.5) 12.9 (7.5)
Systolic blood pressure (mmHg)
Mean (SD) 2325 171.7 (27.5) 173.5 (26.8)
> 170, n (%) 2325 571 (49.18) 602 (51.72)
Diastolic blood pressure (mmHg)
Mean (SD) 2325 92.9 (18.4) 93.6 (17.8)
Advanced imaging performed, n (%) 2277 121 (10.60) 128 (11.28)
Spot positive 249 24 (19.83) 32 (25.00)
Spot negative 249 97 (80.17) 96 (75.00)
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Time to treatment
The median time for stroke onset to randomisation was 3.6 hours (IQR 2.6–5.0 hours) (Figure 4), with 827
(35.6%) participants enrolled within 3 hours and 1571 (67.6%) participants enrolled within 4.5 hours.
The median time to a CT scan was 1.9 hours (IQR 1.4–2.9 hours); 77% of participants had a CT scan within
3 hours of symptom onset and 93% had a CT scan within 4.5 hours (Figure 5). The median time from a CT
scan to randomisation was 1.3 hours (IQR 0.8–2.1 hours) (Figure 6), with 861 (37%) participants randomised
within 1 hour of a CT scan and 1681 (72.3%) participants randomised within 2 hours of a CT scan. The majority
of participants took more than 1 hour to enrol in the trial after a CT scan was performed. The median time
to first dose was 4.1 hours after stroke onset (Figure 7), 25% of participants were treated within 3 hours
of stroke onset and 58% within 4.5 hours.
TABLE 3 Clinical characteristics at randomisation (continued )
Baseline variable N
Treatment group
Tranexamic acid Placebo
Haematoma location, n (%)
Supratentorial – lobar 2325 379 (32.64) 359 (30.84)
Supratentorial – deep 2325 675 (58.14) 696 (59.79)
Infratentorial 2325 73 (6.29) 76 (6.53)
Combination 2325 34 (2.93) 33 (2.84)
Haematoma characteristics
IVH, n (%) 2325 382 (32.90) 363 (31.19)
Intracerebral HV (ml), mean (SD) 2273 24.7 (27.9) 23.3 (26.4)
IHD, ischaemic heart disease; TIA, transient ischaemic attack.
TABLE 4 Adherence to study medication
Adherence
Treatment group
p-valueTranexamic acid Placebo
Number of participants randomised 1161 1164
Treatment, n (%)
All treatment received 1101 (94.8) 1106 (95.0) 0.96
Some treatment received 49 (4.2) 51 (4.4) 0.66
No treatment received 9 (0.8) 6 (0.5) 0.48
Not known 2 (0.2) 1 (0.1) 0.54
Incorrect drug administration,a n (%) 31 (2.7) 26 (2.2) 0.56
Time (minutes) until first dose, median (IQR) 21 (13–33) 21 (13–32) 0.49
a Protocol violations were investigator reported.
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FIGURE 4 Time from stroke onset to randomisation.
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FIGURE 5 Time from stroke onset to CT scan.
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FIGURE 6 Time from CT scan to randomisation.
Hours from stroke onset to first dose
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FIGURE 7 Time from stroke onset to treatment.
DOI: 10.3310/hta23350 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 35
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Sprigg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Consent
The majority of participants were enrolled in the trial after consent by a relative (Table 5). Participants with
more severe stroke (i.e. a higher NIHSS score) were more likely to use relative or doctor consent. Independent
doctor consent had the shortest time from onset to randomisation (3.25 hours) compared with full informed
consent from a relative, which took the longest (4.21 hours).
Primary efficacy outcome
The primary outcome of mRS score at day 90 was determined in 2307 (99.2%) participants; 9 (0.4%)
were lost to follow-up and 9 (0.4%) withdrew from their day 90 follow-up (see Figure 3). There was no
difference in the distribution (i.e. shift) in the mRS score at day 90 after adjustment for stratification and
minimisation criteria [adjusted odds ratio (aOR) 0.88, 95% CI 0.76 to 1.03; p = 0.11] (Figure 8).
TABLE 5 Consent type utilised
Consent type n (%) NIHSS mean score OTR mean time (hours)
Patients with data 2325 13 3.94
Fully informed participant 558 (24.0) 7.58 3.97
Brief participant 260 (11.2) 9.03 3.59
Fully informed relative 996 (42.8) 15.1 4.21
Brief relative 323 (13.9) 16.1 3.75
Doctor 188 (8.1) 18 3.25
OTR, onset to randomisation.
Placebo
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10.7% 15.7% 16.8% 19.1% 14.0% 21.6%
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mRS score
Percentage of total
FIGURE 8 Primary outcome: shift plot of the day 90 mRS score (aOR 0.88, 95% CI 0.76 to 1.03; p-value = 0.11). mRS
score level descriptions: 0= no symptoms; 1= no disability despite symptoms; 2= slight disability, but able to look
after own affairs; 3=moderate disability, but able to walk without assistance; 4=moderately severe disability –
unable to walk or attend to own bodily needs; 5 = severely disabled – bedridden and requiring constant nursing
care; and 6= death. Reproduced from Sprigg et al.1 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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A formal goodness-of-fit test gave no evidence that the proportional odds assumption was violated (p = 0.97).
There was no difference between the tranexamic acid and placebo treatment groups in the proportion of
participants who were dead or dependent (mRS score of > 3: aOR 0.82, 95% CI 0.65 to 1.03; p = 0.08).
Subgroup analysis
When the primary outcome was assessed in prespecified subgroups (Figure 9), the only significant
interaction was between mRS score and baseline SBP (interaction p = 0.016). Participants with a baseline
SBP of < 170 mmHg had a favourable shift in mRS score with tranexamic acid compared with those
participants with a SBP of ≥ 170 mmHg. There was no heterogeneity of treatment effect by time to
enrolment (see Figure 9) whether dichotomised at < 3 hours versus ≥ 3 hours (interaction p = 0.89) or
≤ 4.5 hours versus > 4.5 hours (interaction p = 0.28); similarly, there was no interaction between treatment
effect and time when analysed as a continuous variable (aOR 0.98, 95% CI 0.90 to 1.07; p = 0.69).
In exploratory post hoc analysis, participants with a moderate haematoma size (i.e. 30–60 ml) have a
favourable shift in mRS score with tranexamic acid treatment (aOR 0.66, 95% CI 0.44 to 0.98, p = 0.039),
but the interaction between haematoma size and treatment was not statistically significant (p = 0.84). This
difference was statistically significant when studying 1350 participants with a haematoma size of ≤ 60ml
who were enrolled within 4.5 hours of onset (aOR 0.821, 95% CI 0.67 to 0.9; p = 0.031). However, the
interaction between haematoma size and treatment in patients randomised within 4.5 hours was not
statistically significant (p = 0.55).
Secondary outcomes
Radiological outcomes
There were fewer participants with a haematoma expansion at day 2 in the tranexamic acid group
(265, 25.1%) than in the placebo group (304, 28.7%; aOR 0.80, 95% CI 0.66 to 0.98; p = 0.030) (Table 6).
The mean increase in HV from baseline to 24 hours was also less in the tranexamic acid group [3.72 ml
(SD 15.9 ml)] than in the placebo group [4.90 ml (SD 16.0 ml); adjusted mean difference (aMD) –1.37 ml,
95% CI –2.71 to –0.04 ml; p = 0.043].
Clinical outcomes
Neurological impairment (i.e. mean NIHSS score at day 7) did not differ between the tranexamic acid
group (10.1) and the placebo group (10.3) (aMD –0.43, 95% CI –0.94 to 0.09; p = 0.10) (see Table 6).
Clinical outcomes day 90
There were no significant differences in any of the day 90 functional outcomes between treatment groups:
activities of daily living (as measured by the Barthel Index), mood [as measured by the Zung Depression
Scale (ZDS)], cognition (as measured by TICS-M, verbal fluency), or quality of life [as measured by EQ-5D
health utility score (HUS) and EQ-VAS; Table 7].
Cost outcomes
Length of hospital stay and discharge disposition did not differ between treatment groups (see Table 7).
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Characteristic
Onset to randomisation
Onset to randomisation
Age
Sex
SBP
NIHSS score
IVH
< 3 hours
< 70 years
< 170 mmHg
< 15
≥ 3 hours
≥ 70 years
≥ 170 mmHg
≥ 15
< 30 ml
> 60 ml
≤ 4.5 hours
> 4.5 hours
Female
Male
Yes
No
Yes
No
Yes
No
History of antiplatelet therapy
Spot positive
Haematoma location
Supratentorial lobar
Supratentorial deep
Ethnicity
White
Other
Baseline ICH volume
30–60 ml
Overall
n
818
1489
1561
746
1088
1219
1016
1291
1112
1195
1350
957
739
1568
610
1696
56
193
734
1372
1965
342
1639
361
258
2325
OR (95% Cl)
0.91 (0.70 to 1.17)
0.88 (0.73 to 1.06)
0.84 (0.70 to 1.01)
0.83 (0.67 to 1.03)
0.95 (0.77 to 1.17)
0.89 (0.71 to 1.12)
0.87 (0.71 to 1.06)
0.72 (0.58 to 0.89)
1.05 (0.85 to 1.29)
0.99 (0.76 to 1.30)
0.88 (0.73 to 1.07)
0.88 (0.69 to 1.12)
0.76 (0.58 to 1.00)
0.95 (0.79 to 1.14)
0.92 (0.68 to 1.25)
0.87 (0.73 to 1.03)
1.16 (0.37 to 3.57)
1.40 (0.81 to 2.43)
0.81 (0.61 to 1.07)
0.94 (0.77 to 1.14)
0.90 (0.77 to 1.06)
0.69 (0.47 to 1.02)
0.92 (0.77 to 1.10)
0.66 (0.44 to 0.98)
1.20 (0.68 to 2.14)
0.88 (0.76 to 1.03)
p-value
0.89
0.28
0.41
0.86
0.016
0.89
0.13
0.70
0.96
0.32
0.36
0.84
0.11
Favours tranexamic acid
0.20 0.50 1.0 2.0 5.0
Favours placebo
FIGURE 9 Forest plot of the day 90 mRS scores in the subgroups. Haematoma volume was not prespecified and was
an exploratory post hoc analysis.
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TABLE 6 Radiological outcomes and early clinical outcomes
Outcome n
Treatment group
OR/MD (95% CI) p-value
Tranexamic
acid Placebo
Radiological outcomes
Change in HV (ml) (SD) from baseline to
24 hoursa
2112 3.72 (15.9) 4.90 (16.0) MD: –1.37 (–2.71 to –0.04) 0.043
Participants with haematoma
expansion,b n (%)
2112 265 (25.1) 304 (28.7) Binary OR: 0.80 (0.66 to 0.98) 0.030
Clinical outcomes day 7
Death by day 7, n (%) 2325 101 (8.7) 123 (10.6) Binary OR: 0.73 (0.50 to 0.99) 0.041
NIHSS at day 7, mean score (SD) 1829 10.13 (8.3) 10.29 (8.3) MD: –0.43 (–0.94 to 0.09) 0.10
MD, mean difference.
a Adjusted for baseline HV.
b Haematoma expansion defined as an increase of > 6 ml or a growth of > 33%.
TABLE 7 Day 90 secondary outcomes
Secondary outcome N
Treatment group
OR/MD (95% CI) p-value
Tranexamic
acid Placebo
Death by day 90, n (%) 2325 250 (21.5) 249 (21.4) HR: 0.92 (0.77 to 1.10) 0.37
EQ-5D HUS, day 90 2244 0.34 (0.4) 0.34 (0.4) MD: 0.01 (–0.01 to 0.04) 0.30
EQ-VAS, day 90 2081 48.81 (33.8) 48.34 (33.1) MD: 1.75 (–0.52 to 4.02) 0.13
Barthel Index, day 90 2231 52.92 (44.0) 53.21 (43.7) MD: 1.70 (–0.90 to 4.31) 0.20
TICS-M, day 90 1216 13.57 (12.5) 13.94 (12.8) MD: –0.19 (–1.12 to 0.74) 0.69
ZDS score, day 90 1319 67.28 (29.5) 67.29 (29.9) MD: –0.35 (–2.60 to 1.90) 0.76
Global analysis (Wei–Lachin test), day 90 2307 NA NA MWD: 0.00 (–0.05 to 0.04) 0.85
Length of stay (days) in hospital 2312 63.12 (47.1) 63.73 (48.1) MD: 1.09 (0.97 to 1.24) 0.16
If discharged, days well at home 1007 69.94 (28.6) 72.15 (29.1) MD: –0.72 (–3.73 to 2.28) 0.64
Home discharge, n (%) 2325 465 (40.1) 453 (38.9) Binary OR: 1.14 (0.93 to 1.40) 0.20
Institutionalisation, n (%) 2325 505 (43.5) 506 (43.5) Binary OR: 0.99 (0.83 to 1.18) 0.90
Died by discharge, n (%) 2325 190 (16.4) 205 (17.6) Binary OR: 0.83 (0.65 to 1.07) 0.15
HR, hazard ratio; MD, mean difference; MWD, mean weighted difference; NA, not applicable.
DOI: 10.3310/hta23350 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 35
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Sprigg et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Process-of-care measures
The majority of participants received intravenous blood pressure-lowering treatment (i.e. 75.3% in the
tranexamic acid group and 74.5% in the placebo group) on the first day. By day 7 nearly all participants
had received blood pressure-lowering treatment (i.e. 81.6% in the tranexamic acid group and 83.5% in
the placebo group).
The use of do not attempt resuscitation (DNAR) orders increased from 17% in the first 24 hours, to 22%
by day 7, but there was no difference between the treatment groups (Table 8).
Only 5% of participants underwent neurosurgery, with similar rates for both treatment groups. A total of
10% of participants were transferred to intensive care units (ICUs), with 7% of participants undergoing
ventilation. Rates of ICU transfer and ventilation did not differ between the treatment groups.
Safety outcomes
There were fewer deaths by day 7 in the tranexamic acid group (101, 8.7%) than in the placebo group
(123, 10.6%; aOR 0.73, 95% CI 0.53 to 0.99; p = 0.041).
The number of deaths by day 90 did not differ between the tranexamic acid group (250/1161, 21.5%)
and the placebo group (249/1164, 21.4%; see Table 7). There was no difference in survival between
treatment groups over 90 days (adjusted hazard ratio 0.92, 95% CI 0.77 to 1.10; p = 0.37) (Figure 10).
TABLE 8 Process-of-care measures at days 2 and 7
Day N
Treatment group
All p-valueTranexamic acid Placebo
Day 2
Participants, n 2325 1161 1164 2325
Blood pressure, n (%)
Treatment 2325 851 (73.3) 886 (76.1) 1737 (74.7) 0.39
Treatment route (i.v.) 1737 641 (75.3) 660 (74.5) 1301 (74.9) 0.78
DNAR orders, n (%) 2325 193 (16.6) 199 (17.1) 392 (16.9) 0.26
Day 7
Participants, n 2325 1161 1164 2325
Blood pressure, n (%)
Treatment 2325 947 (81.6) 972 (83.5) 1919 (82.5) 0.59
Treatment route (i.v.) 1919 545 (57.6) 585 (60.2) 1130 (58.9) 0.21
DNAR orders, n (%) 2325 255 (22.0) 254 (21.8) 509 (21.9) 0.59
Neurosurgery received, n (%) 2325 57 (4.9) 64 (5.5) 121 (5.2) 0.60
ICU, n (%) 2325 113 (9.7) 119 (10.2) 232 (10.0) 0.84
Invasive ventilation, n (%) 2325 82 (7.1) 84 (7.2) 166 (7.1) 0.92
ICU, intensive care unit; i.v., intravenous.
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FIGURE 10 Plot of cumulative mortality. HR, hazard ratio.
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Serious adverse events
A total of 1599 events were reported as SAEs, of which 1355 were SAEs and 200 serious adverse
reactions (SARs) (Figure 11). There were no suspected unexpected SAR (Table 9).
Fewer participants experienced safety outcomes and SAEs at day 2 (32.6% vs. 35.8%), 7 (39.3% vs. 42.7%)
and 90 days (44.9% vs. 47.8%) were significantly lower in the tranexamic acid group (see Table 9). There was
no increase in the number of venous thromboembolic events (3.4% in the tranexamic acid group vs. 3.2%
in the placebo group; p = 0.98), or arterial occlusions (MI, acute coronary syndrome or peripheral arterial
occlusion) in the tranexamic acid group (see Table 9).
Seizure was the most common safety outcome, but there was no difference between the treatment groups
[77 (7%) patients in the tranexamic acid group vs. 85 (7%) patients in the placebo group]. Nervous system
disorders were the most common SAEs [149 (13%) in the tranexamic acid group vs. 163 (14%) in the placebo
group], followed by infections [98 (8%) in the tranexamic acid group vs. 116 (10%) in the placebo group].
Protocol violations
A total of 331 protocol violations were reported by investigators, with 87 meeting the protocol definition
of a protocol violation (Table 10). The commonest protocol violation was failure of a participant to receive
all of the allocated treatment, which occurred in 1% of participants.
Events entered by
investigators
(n = 1599)
SUSARs entered by
investigators
(n = 0)
Events: adjudication
complete, n = 1599 (100%)
Adjudication: SAE,
n = 1355 (84.7%)
Adjudication: not SAE,
n = 44 (2.8%)
Adjudication: SAR,
n = 200 (12.5%)
FIGURE 11 Serious adverse events reported by investigators. SUSAR, suspected unexpected serious adverse
reaction.
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TABLE 9 Serious adverse events/reactions
Event
Median (IQR)
days to event
Treatment group, n (%)
p-value
Tranexamic
acid (n= 1161)
Placebo
(n= 1164)
By day
By day 2 379 (32.6) 417 (35.8) 0.027
By day 7 456 (39.3) 497 (42.7) 0.020
By day 90 521 (44.9) 556 (47.8) 0.039
By classification
SAE 1 (0–3) 493 (42.5) 517 (44.4) 0.11
SAR 2 (1–4) 92 (7.9) 95 (8.2) 0.69
Safety outcomes
Death 1 (0–15) 250 (21.5) 249 (21.4) 0.60
ACS or MI 5 (1–53) 11 (0.9) 6 (0.5) 0.24
DVT 15 (10–34) 19 (1.6) 14 (1.2) 0.41
PE 16 (8–29) 20 (1.7) 23 (2.0) 0.58
VTE (combined DVT/PE) 16 (10–30) 39 (3.4) 37 (3.2) 0.98
Seizure/convulsions 1 (0–3) 77 (6.6) 85 (7.3) 0.44
Ischaemic stroke or TIA 9 (2–52) 16 (1.4) 11 (0.9) 0.27
SAEs by subcategory
Blood and lymphatic system disorders 0 (0–4) 1 (0.1) 2 (0.2) 0.41
Cardiac disorders 1 (1–2) 14 (1.2) 10 (0.9) 0.48
Gastrointestinal disorders 1 (0–2) 12 (1.0) 9 (0.8) 0.59
General disorders and administration site conditions 2 (1–3) 2 (0.2) 2 (0.2) 0.95
Immune system disorders 0 (0–1) 1 (0.1) 2 (0.2) 0.51
Infections and infestations 2 (1–3) 98 (8.4) 116 (10.0) 0.14
Injury, poisoning and procedural complications 1 (1–3) 7 (0.6) 10 (0.9) 0.53
Metabolism and nutrition disorders 4 (1–7) 0 2 (0.2) 0.99
Musculoskeletal and connective tissue disorders 1 (1–1) 0 1 (0.1) 0.99
Neoplasms benign, malignant and unspecified 4 (1–5) 3 (0.3) 3 (0.3) 0.89
Nervous system disorders 1 (0–1) 171 (14.7) 189 (16.2) 0.24
Psychiatric disorders 4 (3–5) 1 (0.1) 4 (0.3) 0.26
Renal and urinary disorders 2 (1–4) 14 (1.2) 17 (1.5) 0.66
Respiratory, thoracic and mediastinal disorders 1 (1–2) 4 (0.3) 3 (0.3) 0.72
Skin and subcutaneous tissue disorders 5 (5–5) 2 (0.2) 0 0.99
Vascular disorders 1 (0–2) 7 (0.6) 9 (0.8) 0.64
Miscellaneous 1 (0–3) 7 (0.6) 6 (0.5) 0.81
ACS, acute coronary syndrome; DVT, deep-vein thrombosis; PE, pulmonary embolism; TIA, transient ischaemic attack.
Note
This table gives details on the SAEs experienced up until each participant’s day 7 follow-up; safety outcomes and death are
collected up until day 90. The numbers given in each group are per participant, as opposed to the total number of events.
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TABLE 10 Protocol violations by category
Protocol violation
Treatment group, n (%)
All, n (%)
Tranexamic
acid Placebo
Patients with data 1161 1164 2325
Number of protocol violations entered by investigators 164 167 331
Number adjudicated to not be a protocol violation 129 115 244
Number of protocol violations 35 52 87
Baseline characteristics
Randomisation over 8 hours from onset of symptoms 1 (0.1) 0 1 (0.0)
Baseline cranial imaging shows underlying structural abnormality, for example a
tumour or arterial venous malformation
1 (0.1) 2 (0.2) 3 (0.1)
On anticoagulation 0 (0.0) 1 (0.1) 1 (0.0)
Randomising event was secondary to trauma 1 (0.1) 0 (0.0) 1 (0.0)
Not a primary ICH 1 (0.1) 1 (0.1) 2 (0.1)
Practice during the trial
Subsequent randomisation into another drug or devices trial 1 (0.1) 0 1 (0.0)
Participant does not receive all of the randomised treatment 13 (1.1) 15 (1.3) 28 (1.2)
Consent and reconsent
Failure to obtain any consent – neither brief information sheet/assent nor fully
informed consent
0 (0.0) 3 (0.3) 3 (0.1)
Failure to obtain appropriate, fully informed consent (following brief or
independent physician consent)
0 (0.0) 5 (0.4) 5 (0.2)
Individual taking consent not authorised to take consent on delegation log 2 (0.2) 5 (0.4) 7 (0.3)
Wrong consent form used to obtain fully informed consent 2 (0.2) 4 (0.3) 6 (0.3)
Follow-up assessments performed
Day 2 follow-up – over 2 days past due date 1 (0.1) 1 (0.1) 2 (0.1)
Day 7 follow-up – over 7 days past due date 2 (0.2) 1 (0.1) 3 (0.1)
Day 90 follow-up – over 30 days past the due date 2 (0.2) 6 (0.5) 8 (0.3)
Miscellaneous
Any other major deviation from the trial protocol 8 (0.7) 8 (0.7) 16 (0.7)
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Chapter 4 Discussion and conclusion
Interpretation
In this international multicentre RCT of tranexamic acid after acute ICH, there was no statistically significant
difference in the primary outcome of functional status at day 90. Despite no significant improvement in primary
outcome, there were statistically significant yet modest reductions in the prespecified secondary outcomes of
early death, haematoma expansion and SAEs. There was no increase in thromboembolic events or seizures.
In keeping with an antifibrinolytic effect, tranexamic acid was associated with a modest yet statistically
significant reduction in haematoma expansion and smaller growth in HV, key factors known to influence
outcome after ICH. However, the small reduction in HV growth (i.e. 1.4 ml), and proportion of participants
experiencing haematoma expansion (29% in the placebo group compared with 25% in the tranexamic
acid group) may have been too small to translate into improved functional status in this population.
Therefore, although it is possible that tranexamic acid is not effective at improving outcome after ICH,
an alternative explanation for the study’s findings is that the observed treatment effect was too modest.
The study’s sample size calculation was based on an estimated effect size of an OR of 0.79, which the trial
did not detect. The observed OR was 0.88 and a much larger sample size would be required to detect
this. Indeed, previous RCTs of tranexamic acid in other settings have randomised more than 10-fold the
number of participants to identify more modest effects on bleeding-related deaths after trauma (i.e. an
OR of 0.85)23 and postpartum haemorrhage (i.e. an OR of 0.81).13 Furthermore, an individual patient data
meta-analysis of two RCTs (with > 40,000 participants), published after enrolment in TICH-2 had completed,
has subsequently confirmed that commencing tranexamic acid within 3 hours of the start of bleeding is
necessary to obtain the benefit of tranexamic acid after trauma or postpartum haemorrhage.15 Despite
repeated efforts to encourage investigators to reduce the time to enrolment, the majority of the study’s
participants were enrolled after 3 hours. Recent meta-analysis of individual patient data in 5435 patients has
demonstrated that the probability of haemorrhage growth declines mostly steeply 3 hours after symptom
onset,53 highlighting the need for urgent treatment.
In the same meta-analysis, baseline HV was the strongest predictor of outcome after SICH. The probability
of haematoma growth increased with baseline HV, but peaked at 75 ml.53 In TICH-2, in an exploratory post
hoc analysis, participants with a baseline HV of between 30 and 60 ml, who received tranexamic acid
appeared to have better outcome (aOR 0.66, 95% CI 0.44 to 0.98; p = 0.039; see Figure 9), but the
interaction between HV and treatment was not significant (p = 0.84). Although this could be due to chance
and caution is needed when interpreting subgroups, it is also compatible with the hypothesis that patients
with moderate-size haematomas may be more likely to benefit from haemostatic therapies and, hence,
could be targeted for future studies, as has been postulated with rFVIIa.23,24
The statistically significant interaction demonstrated in this study between baseline SBP and treatment
suggests participants with lower blood pressure were more likely to benefit from tranexamic acid. This finding
could have been confounded by stroke severity, as larger haematomas have increased blood pressure and
worse outcomes.22,26 Despite being the only intervention to date to improve functional outcome after ICH,
early intensive blood pressure-lowering treatment3 remains controversial.11 Although there were no significant
effects on haematoma growth in INTERACT-2,3 secondary analysis suggested blood pressure lowering did
attenuate bleeding in a dose-dependent manner.25 The interaction demonstrated in this study between SBP
and tranexamic acid suggests complementary approaches to reduce haematoma expansion, with haemostatic
and haemodynamic therapies warranting further investigation.
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Unlike other acute ICH studies with rFVIIa24 and aggressive lowering of blood pressure,10 the study found
no evidence of adverse effects. Notably, there was no increase in VTE or seizures in this significantly older
population with more comorbidities than in participants in previous studies of tranexamic acid.13,23 It is
therefore unlikely that any potential benefit of tranexamic acid was offset by harm, as has been suggested
with rFVIIa.24 In a Phase 3 trial, there was no evidence of clinical benefit of rFVIIa, with a reduction in
haematoma expansion but an increased risk in arterial occlusive events.24 Although tranexamic acid and rFVIIa
are both haemostatic agents, tranexamic acid has antifibrinolytic mechanisms and rFVIIa is a procoagulant
and, hence, they have different risk–benefit profiles. Recent studies with rFVIIa have attempted to use the
spot sign to identify those patients at risk of haematoma expansion and, as such, most likely to benefit from
rFVIIa.26,27 However, the trials were stopped as a result of poor recruitment.28 The study has also demonstrated
that selecting large numbers of patients based on the spot sign is not practicable, as only 10% of participants
had advanced imaging performed. Although the presence of the spot sign does improve prediction of ICH
growth, time from onset, antithrombotic therapy and baseline HV remain the strongest predictors.53
Generalisability
The study’s inclusion criteria were deliberately broad, with recruitment from international sites, across
secondary and tertiary care, reflective of the clinical population. However, the study was unable to collect
screening logs across such a large number of sites and, as such, was unable to determine the proportion
of population who would be eligible for haemostatic therapy if it were effective.
Overall evidence
In the systematic review,25 two small RCTs of tranexamic acid with a total of 54 participants were found,
with no clear evidence of benefit or harm associated with tranexamic acid.38,39 Several smaller RCTs of
tranexamic acid in ICH are ongoing,54–58 with a total enrolment of < 1000 participants across all the trials.
A number of these ongoing trials are targeting participants likely to be at greater risk of haematoma
expansion, based on an earlier time window,54,55 spot sign status55,58 and anticoagulation.59 Although an
individual patient data meta-analysis is planned,33 further large randomised trials are needed to confirm or
refute a clinically significant treatment effect of tranexamic acid.
Strengths
The strengths of this study include double-blinding and strong allocation concealment, with low risk of bias,
high adherence to treatment and high completion of follow-up, with very few missing primary outcomes.
The use of an approved brief (see Report Supplementary Material 1) and proxy consent processes allowed
rapid enrolment of patients without capacity, who are important in acute stroke studies. Independent
doctor consent was the most rapid form of consent and may be appropriate in emergency studies,
especially when relatives struggle to make informed decisions. Minimisation techniques were effective,
and the treatment groups were well matched at baseline. The sample size was large, making this the largest
haemostatic therapy RCT after ICH. Pre-study support from the Nottingham Clinical Trials Unit ensured
that approvals were obtained rapidly once the grant was activated, allowing recruitment to begin in a timely
manner. This rapid set-up process led to a large number of sites being activated ahead of schedule, with
recruitment in the UK exceeding initial expectations, which led to early achievement of the stop–go criteria.
The large number of sites participating in the UK would not have been possible without the support of the
NIHR Clinical Research Network in England and adoption of TICH-2 on the study portfolio. The absence
of an effective drug therapy for ICH, in combination with streamlined processes of acute stroke care to
facilitate reperfusion therapies in ischaemic stroke and the absence of competing trials, led to TICH-2
fitting well into the acute stroke clinical pathway and ensured good engagement with clinicians. Finally,
permission was sought and granted to allow co-enrolment into RESTART; an investigator-led, randomised
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trial comparing starting versus avoiding antiplatelet drugs for adults surviving antithrombotic-associated
ICH.60 The TSCs for both studies felt that co-enrolment did not affect the safety of participants or the quality
of the scientific data and yet allowed for both important clinical questions to be answered, something that
the patient and public involvement group strongly supported (20 participants were co-enrolled, 10 in the
tranexamic acid group, 10 in the placebo group).
Limitations
The wide inclusion criteria led to a heterogeneous population of patients, with multiple comorbidities, more
severe strokes, larger HVs and a greater proportion of participants with lobar haematomas and IVH as compared
with other ICH trials.3,22,24,27 This inclusion of older participants with more comorbidities and larger haematomas,
in particular, could have diluted any treatment effect.
As already highlighted, the majority of participants were enrolled more than 3 hours after ICH onset,
which could explain the absence of a significant interaction with time in the subgroup analysis. In 2016,
the protocol for the ongoing RCT CRASH-3 (testing tranexamic acid in traumatic brain injury) was amended
to reduce the time window for eligibility (originally within 8 hours of injury) to patients within 3 hours
of injury.61 The TSC for TICH-2 discussed on a number of occasions whether or not the inclusion criteria
should be amended to limit recruitment to participants within 3 hours of symptom onset in line with other
tranexamic acid studies. However, as the majority of recruitment had been completed, and there are
important pathophysiological differences between ICH and traumatic brain injury, the decision was taken
to leave the inclusion criteria unchanged but to focus on efforts to ensure rapid treatment. Had this been
an adaptive trial design, enrichment could have allowed further recruitment within subgroups where
tranexamic acid was most likely to be effective, such as those patients presenting < 3 or < 4.5 hours after
the onset of symptoms, or those with moderate-sized haematomas. Furthermore, sample size reassessment
to account for the fact that the observed effect size was lower than predicted in the original sample size
calculation may have been beneficial.62
The study did not seek to explore mechanistic approaches by which tranexamic acid could improve
outcome. First, this could be done by addressing how tranexamic acid may reduce haematoma expansion,
and it is thus unclear whether the reduction in number of participants experiencing haematoma expansion
is related to attenuation of primary bleeding, secondary vessel rupture, both or neither. More research is
needed to understand the time course of changes after acute ICH and differences between lobar and deep
haematomas. Although the study collected data on haematoma location and local investigators assigned a
final diagnosis, it is acknowledged that recognising cerebral amyloid angiopathy (CAA) is a challenge and
many of the participants, particularly elderly participants, may have undiagnosed CAA. Further work is
currently being undertaken to analyse participants’ brain images and will be presented at a later date.
Second, beyond antifibrinolytic effects there is increasing recognition that because of its inhibition of
plasmin, tranexamic acid has anti-inflammatory properties. This anti-inflammatory action has been
speculated to be important for the efficacy of tranexamic acid.63 Inflammation is a key contributor to
secondary brain injury after ICH and the effects of tranexamic acid on this warrant further investigation.
Although the recruitment process was simple and enrolment could be done by a doctor, the majority of
participants were enrolled during working hours, due in part to a reliance on clinical research network
staff. Only a small number of hyperacute stroke research centres in the UK have coverage from clinical
research network staff in the evenings and at weekends. It is therefore likely that a large number of
potential participants were not considered for enrolment as they presented with stroke symptoms outside
normal working hours.
Furthermore, requiring the NIHSS score to be measured before randomisation reduced the number of
participants enrolled in the emergency department because of a lack of availability of trained staff, again,
particularly out of hours. For this reason, the study did not collect HV at baseline, as measuring HV is not
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currently part of standard clinical care in the majority of hospitals. It was therefore not possible to minimise
on the basis of HV.
Finally, although the study set up and recruitment in the UK exceeded expectations, set up in international
sites took longer than expected, with governance issues contributing to significant delays. This was the
main contributing factor that necessitated the 1-year contract extension in order to allow recruitment
targets to be met. This delay in starting the study in international sites meant that the majority of
participants were recruited from the UK, limiting international generalisability.
Public and patient involvement
Haemorrhagic stroke was highlighted as a research priority by the Stroke Association and stroke survivors
have been involved throughout the trial, since the conception of the study. The Nottingham Stroke
Research Partnership, comprising stroke survivors and carers, reviewed the proposed study, in an iterative
process, commented on its design and conduct. In particular, the Nottingham Stroke Research Partnership
influenced the approach to taking informed consent within the study. The group felt strongly that
everything should be done to allow as many people suffering from stroke as possible to take part in the
study. In particular, the group recognised that in the emergency situation of an acute stroke it is often
impossible to take in information to allow people to fully decide whether or not they wish to take part
in the study, as a result of speech and processing problems caused by the acute stroke. In this instance,
it was believed that the person would want to be included in such a study, unless there was a medical
reason not to or if they had pre-expressed a desire not to want to take part. The group also recognised
that many people arrive in hospital alone after a stroke without family members present. It was for this
reason that the study sought permission for enrolment after consultation with an independent physician
when no family or friends are present.
Malcom Jarvis and Christine Knott, both stroke survivors, were members of the TSC throughout the duration
of the trial. In addition to shaping the informed consent processes, stroke survivors (i.e. the Nottingham
Stroke Research Partnership group) provided advice on how best to inform participants of the study results,
which included developing a lay summary for the trial, which is available on the study website. Malcolm
Jarvis and Christine Knott helped prepare the primary publication and this report.
Conclusions
The TICH-2 study is the first large multicentre international RCT of tranexamic acid, in acute SICH. There was
no statistically significant improvement in functional status at 90 days. Significant yet modest reduction in
the number of participants with haematoma expansion and fewer early deaths in those allocated tranexamic
acid are consistent with tranexamic acid having an antifibrinolytic effect after ICH. Tranexamic acid was safe,
with fewer SAEs and no increase in thromboembolic events or seizures. Prespecified subgroup analyses
suggested that treatment for participants with lower blood pressure may be beneficial. Although the
analysis did not demonstrate an interaction with time to enrolment, earlier treatment in those patients with
a modest haematoma size (excluding those with very large haematomas, who may have already undergone
haematoma expansion) may be optimal.
Implications for health care
Although there is insufficient evidence to support the routine use of tranexamic acid in clinical practice for
SICH, the results do not exclude a modest but clinically important treatment effect.
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Tranexamic acid is affordable, widely available, easy to administer and appears to be safe. Even a modest
benefit could have a global impact on the excessive burden of mortality and morbidity after ICH.
Recommendations for research
Although a number of smaller randomised trials are ongoing,54–58,64 further large randomised trials are
likely to be needed to confirm or refute a clinically significant treatment effect. Future research should
investigate which subgroups of patients may benefit. Enriching future trial populations with participants
most likely to benefit from haemostatic agents (e.g. those patients presenting early, with moderate
haematomas, excluding participants with predestined poor outcome) may reduce sample size but should
not be done at the expense of increasing the complexity of the study design. Focus must primarily be on
enrolling participants as soon as possible after a diagnosis of ICH. One ongoing study is already seeking
to enrol participants in the prehospital time window.64 Trial design (including participant selection and
consent processes) needs to be streamlined and as fast as possible in this emergency situation. Embedding
trials into the clinical pathway is essential to ensure adequate recruitment and generalisability of results.
Finally, harmonisation of approval processes could reduce set-up time and expense needed to complete
large international studies, thereby reducing research waste.65
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Appendix 1 Definition of safety events
Acute coronary syndrome
Unstable angina
Although there is no universally accepted definition of unstable angina, it has been described as a clinical
syndrome between stable angina and acute MI.
Myocardial infarction
Either one of the following criteria satisfies the diagnosis for an acute, evolving or recent MI:
l typical rise and gradual fall (of troponin) or more rapid rise and fall [of creatine kinase – myocardial
bound (CK-MB)] of biochemical markers of myocardial necrosis, with at least one of the following:
¢ ischaemic symptoms
¢ development of pathological Q waves on the electrocardiogram (ECG)
¢ ECG changes indicative of ischaemia (i.e. ST-segment elevation or depression) or
¢ coronary artery intervention (e.g. coronary angioplasty).
l pathological findings of an acute MI.
Ischaemic stroke
A clinical syndrome characterised by rapidly developing clinical symptoms and/or signs of focal (and at
times global) loss of cerebral function, with symptoms lasting for > 24 hours or leading to death, with no
apparent cause other than that of vascular origin. Classification as being ischaemic is based on results of a
head CT/MRI imaging excluding haemorrhage.
Transient ischaemic attack
A sudden focal neurological deficit of the brain or eye presumed to be of vascular origin and lasts < 24 hours.
Peripheral arterial disease
A sudden blockage of a peripheral artery; the blockage may result from a blood clot, embolism, dissection
or trauma. Symptoms usually start suddenly. Acute peripheral arterial limb occlusion includes the seven
symptoms listed below:
1. severe pain
2. coldness
3. paraesthesia
4. loss of sensation
5. paleness in an extremity
6. lack of pulse in an extremity
7. blue skin in an affected limb.
Acute peripheral arterial limb occlusion can also affect the arteries that carry blood from the kidneys and
the stomach.
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Examples of evidence required:
l clinical
l radiological details, for example angiography.
Seizure/convulsions
Focal or generalised seizures, tonic–clonic seizures or partial seizures; diagnosed clinically after review by an
appropriately trained physician.
Venous thromboembolism
This encompasses both deep-vein thrombosis (DVT) and pulmonary embolism (PE).
Examples of evidence required:
l clinical detail
l DVT –
¢ ultrasound
¢ venography
l PE –
¢ VQ (i.e. a ventilation–perfusion) scan
¢ CT pulmonary angiography scan.
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Appendix 2 Full list of protocol amendments
3 December 2012
The protocol had to be amended following Research Ethics Committee (REC) review. The changes relate to
participant identifiers and the consent process for potential participants who are not able to consent for
themselves and do not have relatives present.
9 October 2013
Update to part B, section 3 (Radiation) on the REC and Research and Development Form.
28 February 2014
Five amendments were made to the protocol.
Amendment 1: extension to follow-up period
It was expected that most patients would continue to improve following their stroke, and that important
changes would be missed in recovery by following patients up only to day 90. Therefore, the follow-up
period was extended to day 365.
Amendment 2: temperature monitoring
The protocol was updated to reflect the Summary of Product Characteristics.
Amendment 3: co–enrolment to the RESTART study
This allowed enrolment into both studies, as long as co-enrolment did not affect the safety of participants,
or the quality of the scientific data and allowed both important clinical questions to be answered.
Amendment 4
Amendment 4 was a clarification of the consent procedures in the emergency situation.
Amendment 5
Amendment 4 was to make typographical changes where required.
4 March 2015
The amendment was the addition of the MRI substudy.
24 July 2015
This amendment was to update MRI substudy consent forms to include a missing initial box and to remove
the participant signature line on the personal legal representative consent form, as the participant would
not sign this form.
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9 November 2015
This was a minor amendment to the MRI substudy consent forms.
26 May 2016
Addition of plasma biomarkers substudy in one centre.
1 September 2016
To apply for a 12-month extension to recruitment, with recruitment planned to be completed by
September 2017 and grant closure by February 2018.
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